Less than 5% of abdominal injuries comprise the duodenum. Treatment is complex with high mortality and morbidity rates. These injuries are usually treated surgically and complications frequently occur. Three cases are presented in this communication in which the injury of the duodenum could not be repaired tension-free. In these cases a Foley balloon catheter was used to close the rupture. After a few weeks, patients were fed through the Foley catheter duodenostomy until a fistular track was formed. On removal of the catheter the fistular track closed spontaneously including the perforation of the duodenum.
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
The original version of this article unfortunately contained a mistake on the fifth and eleventh author names, from Schelto Kruijf to Schelto Kruijff and from Tessa van Ginhoven to Tessa M. van Ginhoven. The corrected author names are shown below.
Schelto Kruijff and Tessa M. van GinhovenPublisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Background
The 2015 American Thyroid Association (ATA) risk stratification system for differentiated thyroid cancer (DTC) is designed to predict recurring/persisting disease but not survival. Previous studies evaluating this system comprised relatively few patients with High Risk and/or follicular thyroid carcinoma (FTC). Therefore, we evaluated response to therapy, risk of recurrence as well as survival in a large population of High Risk DTC patients with a substantial proportion of FTC patients.
Methods
Adult patients, who fulfilled the 2015 ATA High Risk criteria and were diagnosed and/or treated for DTC at a Dutch university hospital between January 2002 and December 2015, were retrospectively included. Response to therapy, recurrence, and mortality characteristics were obtained from patient records. Logistic regression and cox proportional hazards models were used to estimate the effects of ATA High Risk factors on response to therapy, recurrence and survival. Further, disease specific survival (DSS) was analyzed using the Kaplan-Meier method.
Results
We included 236 patients (63% women; 32% FTC) with mean age of 56 years. During follow-up, 49 patients (21%) died due to thyroid cancer. After initial therapy, 38 patients (16%) had excellent response, while 117 (50%) had structural disease. At final follow-up (median 72 months), 69 patients (29%) had excellent response, while 120 (51%) had structural disease. All risk factors, except large pathologic lymph nodes, were inversely related to excellent response at final follow-up. Recurrence occurred in 14% of the patients, and gross extra thyroidal extension at diagnosis increased the chance of recurrence significantly. Ten-year DSS was higher in the initial excellent response than in the structural disease group (100% vs. 61%).
Conclusion
In patients with High Risk DTC, the ATA risk stratification system is not only an excellent predictor of recurring/persisting disease, but also of survival. At final follow-up, half of the patients had persistent disease while one-third showed excellent response. Recurrence rates were higher than expected.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.